HighTower Advisors LLC Has $18.21 Million Holdings in Zoetis Inc. $ZTS

HighTower Advisors LLC decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 39.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 253,412 shares of the company’s stock after selling 166,492 shares during the quarter. HighTower Advisors LLC’s holdings in Zoetis were worth $18,210,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ZTS. RFG Advisory LLC lifted its holdings in Zoetis by 4.9% in the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after buying an additional 80 shares during the period. Quest 10 Wealth Builders Inc. grew its holdings in Zoetis by 4.7% during the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after acquiring an additional 86 shares during the period. Financial Engines Advisors L.L.C. grew its holdings in Zoetis by 4.4% during the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after acquiring an additional 87 shares during the period. Physician Wealth Advisors Inc. raised its position in shares of Zoetis by 17.4% during the 1st quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after acquiring an additional 91 shares during the last quarter. Finally, Smithfield Trust Co raised its position in shares of Zoetis by 4.2% during the 4th quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock valued at $290,000 after acquiring an additional 92 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

ZTS stock opened at $73.64 on Friday. Zoetis Inc. has a 1-year low of $71.45 and a 1-year high of $160.48. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The firm has a market cap of $30.43 billion, a PE ratio of 12.13, a P/E/G ratio of 1.28 and a beta of 0.74. The business’s 50-day moving average price is $76.30 and its two-hundred day moving average price is $99.01.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.19 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is presently 34.93%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Zacks Research lowered Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. UBS Group cut their target price on Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th. Citigroup reduced their target price on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, William Blair reaffirmed a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Zoetis has a consensus rating of “Hold” and a consensus target price of $109.62.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.